McIlrath & Eck’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$54.5K Buy
384
+34
+10% +$5.46K 0.01% 306
2026
Q2
$59K Buy
+350
New +$51.9K ﹤0.01% 337

Other funds holding NBIX

McIlrath & Eck's NBIX Position: Q3 2026 in Review

McIlrath & Eck increased its Neurocrine Biosciences (NBIX) stake by 9.7% in Q3 2026, buying an estimated $5.46K and bringing the position to 384 shares worth $54.5K. The position accounts for 0.01% of the portfolio, ranked #306.

McIlrath & Eck first reported a position in NBIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $59K in Q2 2026. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • McIlrath & Eck held 384 shares of Neurocrine Biosciences worth $54.5K as of Q3 2026.
  • McIlrath & Eck bought 34 Neurocrine Biosciences shares in Q3 2026, an estimated $5.46K.
  • Neurocrine Biosciences made up 0.01% of McIlrath & Eck's portfolio in Q3 2026, its #306 holding.
  • McIlrath & Eck first reported a position in Neurocrine Biosciences in Q2 2026 and has held it in 2 quarters since.
  • McIlrath & Eck's Neurocrine Biosciences position peaked at $59K in Q2 2026.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on McIlrath & Eck's 13F filing for Q3 2026, filed 17 Nov 2026.